1. The provider characteristics and the severity of diabetes were not included for as predictors, due to data limitations. 2. Classification bias for different treatment groups is possible given the way patients were classified. 3. Not all the guidelines suggested DPN medications are included in this study. NSAIDs, or other over-the-counter (OTC) medications are not included.
Objectives
To compare patient characteristics between newly treated DPN patients receiving mono-pharmacotherapy and those receiving combination pharmacotherapy Patients were included if they were ≥18 years at the time of their first DPN prescription for tricyclic antidepressant (TCAs), opioids, duloxetine, gabapentin, pregabalin, or lidocaine. 3.
Methods

Database Design
They were classified as having mono-or combination pharmacotherapy (time between the first and second medicine was within 30 days). If there was 60-day prescription-filled gap for the index medicine, the prescription was classified as discontinued. Switch or add-on groups were categorized based on continuation of the index medicine.
Analysis
1.
A chi-square test was done to compare the baseline characteristics between mono-and combination pharmacotherapy 2.
A simple proportional hazards model was conducted for comparing time to discontinue, switch, or add-on. 3.
Multiple logistic regression was used for identifying predictors of combination pharmacotherapy.
Figure 1 The Algorithm for Defining Treatment Groups
Patients who have 60-day prescriptions after index date N=72,614
Age ≥ 18 at index date
N=70,681
Patients who have at least 1 year enrollment after index date
N=54,617
Patients who have at least half year enrollment before index date N=32,400 Table 1 Demographic Characteristics of DPN Patients 1. The top three index medicines were gabapentin (55.7%), opioids (13.1%), and pregabalin (12.9%) in the mono-pharmacotherapy group, and opioids+ gabapentin (27.1%), TCAs+ gabapentin (17.6%), and duloxetine+ gabapentin (8.6%) in combination group.
2. Overall, combination pharmacotherapy patients have a lower proportion in non-switch than mono-pharmacotherapy patients (40% vs. 58%), but have a higher percentage in discontinuation (47% vs. 34%) switch (5% vs. 4%) and added-on (7% vs. 4%). Patients on combination pharmacotherapy were 130% more likely to discontinue than patients on mono-pharmacotherapy (95%CI = 1.13-1.51, p<0.001).
There was no statistically significant difference in time to add-on (p=0.069).
There was no statistically significant difference in time to switch (p=0.254). Table 2 Clinical Co-morbidities of DPN Patients Table 3 Characteristics associated with combination pharmacotherapy (co-morbidities) 3 . Patients who are female, with >7 co-morbidities, and who had depression, or arthritis were more likely to start with combination pharmacotherapy. Patients who are older than 65, and those who have hypertension were less likely to start with combination pharmacotherapy.
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